Skip to content
Homepage
Clinic directory

Clinics in Baltimore, Pennsylvania

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Baltimore, PA

Stem Cell Therapy clinics in Baltimore

Baltimore supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Johns Hopkins Hospital, University of Maryland Medical Center, and MedStar, and stem cell practice in the area spans Mount Vernon, Fells Point, and the Inner Harbor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Maryland regulates physician practice through the Maryland Board of Physicians. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Johns Hopkins and NIH campus activity drive academic trial density. The 6 Baltimore clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Maryland Board of Physicians licensure checks.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on Pennsylvania's stem cell therapy rules.

Pennsylvania cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Pennsylvania for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. The state hosts substantial academic regenerative research at Penn, Pitt, and CHOP.

  • Pennsylvania Medical Practice Act, 63 PS Section 422.1 et seq
    Establishes MD licensure and discipline through the Pennsylvania State Board of Medicine.
  • Pennsylvania Osteopathic Medical Practice Act, 63 PS Section 271.1 et seq
    Establishes DO licensure and discipline through the Pennsylvania State Board of Osteopathic Medicine.
  • Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 PS Section 201-1 et seq
    Empowers the Attorney General and private plaintiffs to pursue deceptive marketing claims against providers making unsupported clinical claims.

The FDA has issued warning letters to Pennsylvania clinics offering stem cell and exosome therapies. The Pennsylvania State Boards of Medicine and Osteopathic Medicine have disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Pennsylvania Attorney General has used the Unfair Trade Practices and Consumer Protection Law to pursue providers making unsupported clinical claims. Penn, Pitt, and CHOP operate compliant IND-based regenerative research programs. Federal warning letters apply nationally.

Sources: fda.gov · dos.pa.gov · attorneygeneral.gov

Stem Cell Therapy in Baltimore, answered.

Most stem cell therapies at private Baltimore clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Maryland regulates physician practice through the Maryland Board of Physicians.

Baltimore sits in the premium metro tier. Single-joint autologous bone marrow or adipose injections typically run $5,000 to $15,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $10,000 to $25,000, and full multi-session protocols can reach $20,000 to $50,000. Exosome add-ons range $4,000 to $8,000. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Baltimore clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at Johns Hopkins Hospital, University of Maryland Medical Center, and MedStar periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Baltimore or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the Maryland Board of Physicians and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with federal 21 CFR 1271.

Treatment guide

Learn about Stem Cell Therapy

What it is, how it works, and what to expect.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology